Position in ROIV
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$10,617,000
+$2,307,000 QoQ
Shares Held
300,000
0.0% QoQ
Ownership
0.042%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#101
of 494 holders
Holding Since
Mar 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Impax Asset Management Group plc holds $114,915,981 across 7 Biotechnology names. ROIV ranks #6 (9.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
130,000 | $41,091,700 | |
| 2 | TVTX |
Travere Therapeutics, Inc.
|
300,000 | $17,043,000 | |
| 3 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
435,000 | $16,277,700 | |
| 4 | CYTK |
Cytokinetics Inc
|
165,000 | $14,056,350 | |
| 5 | TECH |
BIO-TECHNE Corp
|
195,000 | $13,776,750 | |
| 6 | ROIV |
Roivant Sciences Ltd.
This page
|
300,000 | $10,617,000 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,134 | $2,053,481 |
All Filings in ROIV
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,617,000 | 300,000 | Shares | Defined | 2026-08-11 | |
| 2026-03-31 | $8,310,000 | 300,000 | Shares | Defined | 2026-05-12 | |
| 2025-12-31 | $11,935,000 | 550,000 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $27,234,000 | 1,800,000 | Shares | Defined | 2025-11-06 | |
| 2025-06-30 | $22,540,000 | 2,000,000 | Shares | Defined | 2025-08-08 | |
| 2025-03-31 | $20,180,000 | 2,000,000 | Shares | Defined | 2025-04-29 | |
| 2024-12-31 | $23,660,000 | 2,000,000 | Shares | Defined | 2025-02-04 | |
| 2024-03-31 | $16,864,000 | 1,600,000 | Shares | Defined | 2024-04-30 | |
| No filing history on record for this holder in this stock. | ||||||